Lingke
X

 

      +86 0571-87711179

ychen1@lynkpharma.com


lynk Pharmaceutical (Hangzhou) Co., Ltd.    |    浙ICP备18056091号-1   |   Powered by www.300.cn    |   Manager

CONTACT US

website

Search

291 Fucheng Road, Bldg 5-402, Jianggan, Hangzhou,
Zhejiang 310018, China

Lynk Pharmaceuticals enters exclusive licensing agreements develop RAS inhibitors with a novel MOA
{{= $!info.name}}
HANGZHOU, China, July 27, 2020 /PRNewswire/ -- Lynk Pharmaceuticals is pleased to announce exclusive licensing agreements with Kobe 
University and RIKEN Research Institute to develop RAS inhibitors with a novel MOA.
Lynk Pharmaceuticals successfully out-licensed a preclinical candidate
{{= $!info.name}}
Lynk Pharmaceuticals successfully out-licensed a preclinical candidate to a US company in April, 2020. Details will be announced at a later date.
On May 8, 2020, Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, and Lynk Pharmaceuticals jointly founded IBMC-Lynk New Drug Discovery Center.
{{= $!info.name}}
On May 8, 2020, Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, and Lynk Pharmaceuticals jointly founded IBMC-Lynk
New Drug Discovery Center.
Lynk Pharmaceuticals' SPF Laboratory Animal Facility Passed Inspection
{{= $!info.name}}
Lynk Phamaceuticals' Laboratory Animal Facility has passed on-site inspection performed by the Office of Zhejiang Province Laboratory Animal
Management Committee and obtained the Laboratory Animal Use License in Dec. 6, 2019.
2019 New drug research and development symposium, Hilton, Guangzhou
{{= $!info.name}}
Dr. Zhao-Kui (ZK) Wan, founder & CEO, of Lynk Pharmaceuticals, was invited to present at the symposium

To make life more valuable, Lynk Pharmaceuticals challenges “undruggable” targets
{{= $!info.name}}
To make life more valuable, Lynk Pharmaceuticals challenges “undruggable” targets
上一页
1
2